Although oncogenic PTPRs are attractive molecules for the development of targeted therapies, the development of PTPR inhibitors remains challenging due to the high level of conservation in the active site of tumor suppressor and oncogenic PTPRs (201). Here, PTPRR is linked to neoplasm.